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Liposomal hamycin in the control of experimental aspergillosis in mice:
effect of phosphatidic acid with and without cholesterol
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Hamycin incorporated into liposomes containing phosphatidylcholine (SPC) and
phosphatidic acid (PA) had reduced toxicity and an enhanced antifungal activity in
experimental aspergillosis in balb/c mice. Incorporation of cholesterol into lipo-
somes led to a dose dependent decrease in the toxicity of hamycin. The LD^ (mg/kg)
of hamycin contained in SPC/cholesterol/PA (molar ratio 4:5:1) liposomes was 2-8
whereas that in SPC/PA liposomes (molar ratio 9:1) was 0-35. Although the free
drug had little or no protective effect on the animals, those administered liposomal
hamycin at an equivalent dose (01 mg/kg) in the absence of cholesterol (SPC/PA;
molar ratio 9:1) showed 90% survival after seven days of therapy. On the other
hand the presence of cholesterol in the carrier phosphatidic acid liposomes (SPC/
cholesterol/PA; molar ratio 4 :5 :1) at a similar dose (0-1 mg/kg) led to a 60%
survival over the same time period. Hamycin incorporation in phosphatidic acid
liposomes both in the presence or absence of cholesterol was found to be effective in
reducing the fungal load in lung, liver, spleen and kidney. Studies with distribution
of hamycin in various tissues by HPLC showed a significant reduction in the
concentration of the liposomal drug in circulation as compared to those seem after
administration of free drug.
Introduction
Hamycin, an aromatic heptaene isolated from Streptomyces pimprina, has been used
topically against a variety of fungal infections (Thimmalachar & Narasimhan, 1987).
The interest in the use of aromatic polyenes against fungal infections is because their in-
vitro antifungal activity on eukaryotic membranes is two to three orders of magnitude
higher than that of their non aromatic counterparts (Hammond, 1977; Cybulska et al.,
1983). Hamycin acts by binding to ergosterol in the plasma membrane of the fungal cell
leading to the formation of pores which allow metabolites to leak out, resulting in cell
death. Parenteral administration of hamycin is associated with acute toxicity (Dave &
Kaul, 1964; Williams et al., 1965) which appears to be related to the stability, residence
time, and the intrinsic permeability properties of the polyene—sterol complex
(Mazerski, Bolard & Borowski, 1983).
Liposomes are being increasingly exploited as a drug delivery system in the treatment
of fungal infections (New, Chance & Heath, 1981; Lopez-Berestein, et al., 1987) to
reduce the in-vivo toxicity and enhance the antifungal activity of the drug. A number
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of laboratories including ours have reported on the reduced toxicity of liposomal
amphotericin B leading to a significant improvement in its therapeutic index in the
treatment of systemic fungal infections (Tremblay et al, 1984; Lopez-Berestein, 1986;
Ahmad, Sarkar & Bachhawat, 1989). Furthermore our laboratory (Moonis, Ahmad &
Bachhawat, 1992) and Mehta et al. (1991) have shown that liposomal hamycin is
effective in vivo.
In the present studies we have used liposomes bearing a strong negative surface
charge so as to reduce their circulation time in vivo as macrophages are reported to
have a high affinity towards negatively charged liposomes (Senior, 1987). We have
investigated the effect of phosphatidic acid liposomes on in-vivo toxicity and antifungal
activity of hamycin. We also present data on the tissue distribution of liposomal
hamycin in the presence and absence of cholesterol in normal mice and compared with
that in mice infected with Aspergillus fumigatus.
Materials and methods
Drugs, lipids and chemicals
Hamycin was a gift from Dr S. R. Naik of Hindustan Antibiotics Ltd., (Pimpri, India).
Soya phosphatidylcholine (SPC) was from Dianorm, (Germany), egg phosphatidic acid
(PA) was from Sigma Chemical Co, (St. Louis, USA) and cholesterol was from the
Centre for Biochemicals, (New Delhi, India). All other reagents used were of analytical
grade.
Animals
Male balb/c mice (body wt, 20-25 g) were obtained from the animal house facility of
the National Institute of Nutrition, (Hyderabad, India) and maintained in our animal
house.
Animal model for aspergillosis in balb/c mice
A. fumigatus strain V.P. chest 256 isolated from a patient was supplied by Dr Z. U.
Khan of V.P. Chest Institute, Delhi. The animal model for aspergillosis in balb/c mice
was established as described by Ahmad, Sarkar & Bachhawat (1989ft). In brief 1-8 x 107
viable A. fumigatus spores were suspended in sterile saline and injected into balb/c mice
via a tail vein.
Preparation of hamycin suspension
Hamycin suspension was prepared as described by Moonis et al. (1992). In brief, an
appropriate volume of stock hamycin solution (200 mg/L in methanol) mixed with
0-9% NaCl containing 1% Tween—80. The suspension was sonicated in a water bath
sonicator for 30 min under nitrogen to completely disperse the drug.
Liposome preparation
Liposomal hamycin was prepared as described by Moonis et al. (1992). The lipid
compositions used for the preparation of liposomes were SPC/PA (molar ratio, 9:1)
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and SPC/cholesterol/PA (molar ratio, 4 :5:1) . In brief, the lipids (1 mg hamycin for
45 mg lipids) were dissolved in chloroform/methanol (2:1 v/v) and a solution of
hamycin in methanol added. The organic solvents were evaporated under vacuum using
rotary evaporator and kept in a dessicator overnight. The thin dry film obtained was
resuspended in 0-15 M NaCl and sonicated for 45 min under nitrogen in a bath type
sonicator (Model Decon FS-200, Utrasonic Ltd., England). Free hamycin was removed
by overnight dialysis at 4°C in 200 volumes of 0-9% NaCl with two changes. The
amount of hamycin entrapped in liposomes was determined both spectrophotometri-
cally at 380 nm and by HPLC at 355 nm (Moonis et al, 1992). The intercalation
efficiency was between 60-80%.
LDX determination
Free hamycin (0-0625-0-5 mg/kg) and liposomal hamycin (0-125-40 mg of hamycin/
kg) were injected iv into four groups (five mice per group) of balb/c mice (weight
20-25 g) such that the logarithms of successive dosage levels differed by a constant (d),
the geometric factor being denoted by R where d = log R. Survival was checked over a
period of four days. L D ^ were calculated by the formula log (LDjJ = log dose
(minimum) + log ratio (f+ 1) where f is a function of the mortality taken from the tables
in Weil (1952). The confidence level of the assay was 5%.
Treatment of infected mice
Seventy male balb/c mice were infected with 1-8 x 107 A. fumigatus spores iv via the tail
vein. After 24 h, mice were divided into groups of ten. The first and second groups
received 005 and 01 mg/kg hamycin in SPC/PA liposomes respectively whereas the
third, fourth and fifth groups received 0 1 , 0-25 and 0-5 mg/kg hamycin in
SPC/cholesterol/PA liposomes respectively. The sixth group was administered
01 mg/kg free hamycin and the last group was the untreated control group.
The in-vivo antifungal activity of liposomal hamycin was evaluated on the basis of
survival and the number of fungal cfu in homogenates of the lung, liver, spleen and
kidney. Survival was checked for seven days after therapy. The cfu in various organs
was determined as follows: two animals from each group was sacrificed on alternate
days after therapy and their lung, liver, spleen and kidney were removed aspetically,
weighed and homogenized in 0-9% NaCl. Serial dilutions of the homogenate were
plated on Sabouraud Dextrose medium. Colonies were counted after 48 h incubation at
37°C.
Statistical analysis of cfu and survival
The cfu data were statistically analysed by the method of analysis of variance of one
way classification as described by Snedecor & Cochran (1968). Since the data were in
the form of cfu counts and were highly variable (some values being 0) a log transforma-
tion was made on the values of the cfu counts + 1 . Heterogeneity of means for the
respective organs was tested by the F-ratio of treatment variance to the experimental
error variance. The latter was used to find the standard error of difference between the
pairs of means by calculating the observed /-value and comparing it with the tabular
/-value of degree of freedom. The survival data was analysed by using the Chi-squared
with Yates correction and by Fisher's exact test.
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HPLC analysis of hamycin
The HPLC system for the analysis of hamycin was as described by Moonis et al. (1992).
The mobile phase was 0-005 M EDTA-Methanol (2:8 v/v) and the column was
Hypersil C,8 (Shandon Scientific Ltd, Cheshire, UK). Detection of hamycin was by UV
absorbance at 355 nm. Peak areas were determined using a PC integrator attached with
the HPLC system. Standard curve linearity was determined by injecting 20 /*L of the
appropriately diluted hamycin from a stock solution (10 mg/L in methanol) in dupli-
cate. The areas under the peak areas were plotted against the amount of drug to obtain
standard curve. Correlation coefficient (r2), for the linear regression of peak areas
versus concentration range between 0012-0-2 fig hamycin was greater than 0-96.
Estimation of liposomal hamycin
Twenty /xL of hamycin was injected in duplicate into the HPLC. The peak area
obtained after injection of methanol lysed liposome was compared with that of the
hamycin standard to calculate the percentage intercalation.
For analysis of hamycin spectrophotometrically, an aliquot of liposome was lysed
with methanol and absorbance was read at 380 nm against a methanol blank. The
absorbance obtained was compared with the absorbance of standard hamycin solution
at 380 nm to calculate percentage intercalation.
Recovery of hamycin from tissue and serum
For recovery of hamycin from various organs and serum, groups of five mice were
killed and various organs including blood were removed. Pooled organs (0-5 g) and
pooled serum (0-5 mL) were homogenized in 2 mL of methanol containing 10 /zg of
hamycin. The samples were centrifuged at 9000 # for 15 min and 20 fiL of the
supernatant was injected into the HPLC. The amount of hamycin was estimated as
described above.
Tissue distribution of liposomal hamycin
Hamycin was assayed in normal and infected mice killed 1 h following iv administra-
tion of liposomal hamycin. Groups of six mice were killed, blood and lung, liver, spleen
and kidney were taken out and frozen until analysis. In the case of hamycin incor-
porated in SPC/cholesterol/PA liposomes, tissue distribution studies were also per-
formed 24 h after liposomal administration as the drug (dose 1-5 mg/kg) could still be
measured 24 h after administration. Pooled organs (0-5 g) were homogenized in
methanol, centrifuged and the supernatant was taken for HPLC analysis. For serum,
1 mL of methanol was added to 0-5 mL of pooled serum and centrifuged at 9000 g for
15 min. The concentration of hamycin assayed in the various organs was multiplied by
the recovery factor. In the case of SPC/PA liposomes, at 1 h, because of the low dose
administered (0-2 mg/kg), additional hamycin (1 mg/L) was added while homogenizing
the tissue samples. The concentration in the sample was estimated by subtracting the
additional added amount from the total concentration measured.
 by guest on February 9, 2011
jac.oxfordjournals.org
D
ow
nloaded from
 
Control of experimental aspergjllosis in mice 573
Table I. LD,,, of various formulations
Formulation tested
Free hamycin
SPC/PA liposomes
SPC/cholesterol/PA
SPC/cholesterol/PA
liposomes
liposomes
of negatively
Molar :
9:1
6 : 3 :
4 : 5 :
ratio
1
1
charged
LD*
liposomal hamycin
(mg hamycin/kg)
017
0-35
0-71
2-80
LD,,, was calculated by the method of Weil (1952). The experiments were repeated twice
with no variation in the results. SPC, Soya phosphatidylcholine; PA, phosphatidic acid.
Results
Animal model for infection
Disseminated fungal infection in the lung, liver, spleen and kidney was observed after
injection of 1-8 xlO7 A. fumigatus spores via the tail vein (data not shown). The
infected animals survived up to two days which gave sufficient time for administration
of hamycin therapy for comparative evaluation.
Effect of phosphatidic acid and cholesterol on the toxicity of liposomal hamycin
The LDy, of various formulations of phosphatidic acid liposomes are given in Table I.
Addition of cholesterol had a marked effect in reducing the toxicity of liposomal
hamycin. A 4-2-fold reduction in the toxicity of hamycin in cholesterol containing
liposomes (SPC/cholesterol/PA, molar ratio 6:3:1) was observed. A further increase
in the LDjo of hamycin in SPC/cholesterol/PA liposomes was observed when choles-
terol was incorporated at a molar ratio of 4 :5 :1 showing a 16-fold reduction in the
toxicity of hamycin as compared to that due to the free drug. The maximum tolerated
dose (MTD) of SPC/PA liposomes in infected animals was 0-22 mg/kg whereas the
MTD for SPC/cholesterol/PA liposomes was 1-8 mg/kg.
Survival and fungal load in infected animals with liposomal hamycin therapy
The survival pattern of animals on various days after therapy is shown in Figure 1. The
data shows only 40% survival of infected animals after 3 days of infection and 100%
mortality after the fourth day. Similar survival pattern (50% survival on the third day;
with 100% mortality thereafter) was observed with infected animals which received
01 mg/kg of free hamycin. In contrast, the animals which received a single iv dose of
005 mg/kg of hamycin in SPC/PA liposomes (molar ratio 9:1) showed 20% survival
seven days after therapy. Animals which received 0-1 mg/kg of hamycin in SPC/PA
liposomes showed 90% survival after seven days of therapy. Administration of
0-25 mg/kg hamycin in SPC/PA liposomes induced high toxicity resulting in the
immediate death of the mice. Incorporation of 01 mg/kg hamycin in
SPC/cholesterol/PA liposomes produced 60% survival of animals after seven days of
therapy. Increasing the dose of the drug in SPC/cholesterol/PA liposomes led to an
increase in survival rates. Animals which received 0-25 mg/kg or 0-5 mg/kg
SPC/cholesterol/PA liposomes showed 80% survival after the 7th day of therapy.
The fungal load in various organs on alternate days after therapy (up to seven days)
with various liposomal formulations of hamycin is presented in Table II, data from
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Days after therapy
Figure 1. Survival of infected balb/c mice given hamycin therapy in phosphatidic acid liposomcs in the
presence or absence of cholesterol. Infected animals (n = 10) were given liposomal hamycin therapy 24 h
after infection with A. fumigatus spores. Yates correction of the chi-squared analysis and Fisher's exact test
indicated significant differences between the groups (P < 0-001, two tailed) on the fifth and seventh days after
therapy whereas differences were insignificant on the third day after therapy. O, untreated controls; • , free
hamycin (0-1 mg/kg); A , hamycin in SPC/PA liposomes at 0-05 mg/kg; A , hamycin in SPC/PA liposomes at
0-1 mg/kg (single experiment using 20 mice); Q, hamycin in SPC/cholesterol/PA liposomes at 0-1 mg/kg.
Values arc expressed as mean % survival of animals from two experiments. The vertical error bars represent
Moonis et al. (1992) for free hamycin has been included for comparison. Liposomal
hamycin in the presence or absence of cholesterol induced a marked reduction in cfu in
all organs as compared to that in untreated animals and in animals treated with free
drug. The cfu counts obtained after therapy with SPC/PA liposomes were not signifi-
cantly different from those observed for SPC/cholesterol/PA liposomes at the same
dosage of liposomal hamycin (01 mg/kg).
Recovery of hamycin from tissues and serum
Recovery of hamycin from tissues and serum ranged from 64% to 88%. The percent-
age recovery from lung, liver, spleen, kidney and serum were 77, 73, 64, 88 and 82,
respectively.
Tissue distribution of hamycin contained in phosphatidic acid liposomes in normal and
infected mice
Tissue distribution of hamycin in normal animals 1 h after the administration of the
liposomal drug is shown in Figure 2. Considering the recovery of the drug from tissues
(64-88%), a less than two-fold difference in drug concentration in various organs may
not be highly significant. However, differences in tissue levels above two-fold could be
significant. The concentration of hamycin in the lung with SPC/cholesterol/PA lipo-
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Table II. Fungal load in various organs of infected mice on alternate days after therapy with free
hamycin or negatively charged liposomal hamycin
Formulation
Tested
Free
hamycin
(01 mg/kg)
SPC/PA 9:1
(0-05 mg/kg)
SPC/PA 9:1
(0-1 mg/kg)
SPC/cholesterol/
PA4:5:1
(0-1 mg/kg)
SPC/cholesterol/
PA 4:5:1
(025 mg/kg)
SPC/cholesterol/
PA 4:5:1
(05 mg/kg)
Days after
therapy
1
3
1
3
5
7
1
3
5
7
1
3
5
7
1
3
5
7
1
3
5
7
lung
3-7±O01»*
2-7 ±002**
3-4±O15
3-6±0
30 ±0-02
0
2-7±O03**
2-7 + O01**
2-6 ±0
0
2-6±O01**
2-4 ±O02**
21 ±O03
0
2-4 ±001
21 ±002
1-5±O1
0
2-9 ±0
2-8 ±0
l-5±O06
0
Mean Log
liver
5-4±O18*
4-6 ±0-03*
4-9 ±O05
3-5 ±0
3-0±O16
2-3±O15
4-6 ±001*
4-2 ±0-43*
40 ±0-33
3-5 ±O04
4-4 ±001*
4-0±O17*
3-8 ±0
31 ±022
4-6±O10
4-4±O19
3-5 ±O05
3-5±01
4-2 ±009
3-9 ±030
3-6 ±025
3-2±O14
cfu (±S.E.)
spleen
4-7 ±004
3-6±01
4-4 ±001
2-5±0
2-3 ±009
l-7±O01
4-6 ±O02
31±O19
2-2 ±005
0
4-4±O13
3-4 ±0-20
2-2 ±0
11 ±069
4-4 ±004
3-5 ±0-03
30 ±01
l l ± O 7
4-4 ±O02
3-5 ±0-30
21 ±0-2
11 ±069
kidney
41 ±009*
3-4 ±034
40±Ol
3-9 ±025
3-5±O13
3-4 ±0
3-3±O19
3-2 ±0*
2-8 ±008
2-8 ±004
3-6 ±0
3-5±O10*
31 ±O04
2-6 ±O08
3-4 ±025
3-3±O01
3-1 ±01
2-7±01
30 ±0
2-9 ±O02
2-9 ±0
2-5±O01
Two animals from each group were killed at each time point for cfu counts. The analysis of variance
between free drug, hamycin incorporated in SPC/PA and SPC/cholesterol/PA liposomes (0-1 mg/kg) revealed
that the treatment means were heterogeneous on various days after therapy for the respective organs at the
5% level (*) and 1% level (••). The analysis of variance between SPC/PA and SPC/cholesterol/PA at
01 mg/kg was not significant except for the lung at the 1 % level on third and fifth day after therapy and the
liver on the 1st day after therapy (5% level). SPC, Soya phosphatidylcholine; PA, phosphatidic acid. The
data for free hamycin are taken from Moonis et al. (1992).
somes was 2-9-fold higher than that previously observed by Moonis et al. (1992) with
free drug. In serum on the other hand a significant decrease in the concentration of
hamycin was observed with liposomal preparations containing SPC/PA (41-fold) and
SPC/cholesterol/PA (3-8-fold) as compared to that previously obtained with the free
drug, (Moonis et al., 1992).
The distribution of hamycin in the tissues of infected animals 1 h after the adminis-
tration of the liposomal drug is shown in Figure 3. In the lung there was a 2-8-fold
decrease in the concentration of hamycin with SPC/PA liposomes as compared to that
obtained with free drug (Moonis et al., 1992). In spleen on the other hand there was a
33-fold increase in the concentration of hamycin SPC/PA liposomes and a 1 -9-fold
enhancement with SPC/cholesterol/PA liposomes in comparison with the free drug
(Moonis et al., 1992). In serum the concentrations of hamycin were reduced by a factor
of 4-4 and 40 for the liposomal preparations (SPC/PA and SPC/cholesterol/PA) in
comparison with the concentrations previously reported due to the free drug (Moonis
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Lung Liver Spleen Kidney Serum
Figure 2. Organ and serum concentration of hamycin I h after iv administration to mice in phosphatidic
acid liposomes with ( • ) and without ( • ) incorporation of cholesterol. Mice were injected 02 mg/kg
hamycin in SPC/PA liposomes and 1-5 mg/kg hamycin in SPC/cholesterol/PA liposomes. For the purpose of
comparison both the doses have been normalized to 1 mg/kg. Bars represent the S.D. of duplicate samples
obtained from pooled organs of six mice.
Lung Liver Spleen Kidney Serum
Figure 3. Organ and serum concentration of hamycin 1 h after iv administration to infected mice in
phosphatidic acid liposomes with ( • ) and without (D) incorporation of cholesterol. Mice were injected
02 mg/kg hamycin in SPC/PA and 1-5 mg/kg hamycin in SPC/cholesterol/PA liposomes. Other experimental
protocols are described in the legend to Figure 2.
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Lung Liver Spleen Kidney
Figure 4. Organ concentration of hamycin 24 h after iv administration in phosphatidic acid liposomcs m
the presence of cholesterol (SPC/cholesterol/PA) in normal (Q) and infected ( • ) mice. E>ose of liposomal
hamycin injected was 1-5 mg/kg. For the purpose of comparison dose of hamycin has been normalized to
1 mg/kg. Bars represent the S.D. of duplicate samples obtained from pooled organs of six mice. Hamycin was
not detectable in serum.
et al., 1992). Tissue distribution of hamycin in SPC/PA Hposomes could not be
determined at 24 h as the amount of injected drug with this formulation was too low
(0-2 mg/kg) to be accurately estimated, and a higher dose could not be administered
due to toxicity. Figure 4 shows the tissue distribution of hamycin administered as a
liposomal preparation (SPC/cholesterol/PA; molar ratio 4:5:1), 24 h following
administration, in normal and infected animals. In the lung there was a 2-7-fold
increase in the concentration of hamycin in infected animals whereas in kidney there
was a 1-8-fold decrease. In liver and spleen the hamycin concentrations were compar-
able in both normal and infected animals.
Discussion
In the present communication we have shown that intercalation of hamycin into
phosphatidic acid liposomes significantly reduces the toxicity as well as enhances the in-
vivo antifungal activity of hamycin in experimental aspergillosis. The observed reduc-
tion in the toxicity of hamycin in vivo is determined by the amount of cholesterol
incorporated into phosphatidic acid liposomes. This is consistent with our earlier
observations (Moonis et al., 1992) and those of other investigators (Mehta et al, 1991).
The reason for the reduced toxicity of hamycin in cholesterol-containing phosphatidic
acid liposomes may be due to their reduced circulation time which may minimize the
deleterious effects arising from the interaction of the drug with the RBC's (Juliano &
Stamp, 1975). The toxicity of hamycin in cholesterol-containing phosphatidic acid
liposomes was significantly lower than that of the free drug and drug intercalated into
neutral liposomes (Moonis et al, 1992).
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We suggested that due to similar binding affinities of aromatic polyenes to fungal as
well as host cell sterol, hamycin cannot preferentially bind to ergosterol in the presence
of liposomal cholesterol (Moonis et al., 1992). To circumvent this we designed
liposomes having strong negative surface charges which are known to be rapidly taken
up by the reticuloendothelial system thus accelerating their clearance from the circula-
tion. This could in turn augment the hamycin-ergosterol interaction in diseased organs
leading to enhanced antifungal activity in vivo. Tissue distribution studies revealed an
enhanced uptake of liposomal hamycin at infected sites with a concomitant decrease in
the serum hamycin concentration. The enhanced in-vivo antifungal activity of hamycin
contained in phosphatidic acid liposomes could be due to the increased interaction of
hamycin with ergosterol as a consequence of the enhanced uptake by the macrophages.
In the same disease model, hamycin intercalated into neutral liposomes at an equivalent
dose (01 mg/kg) was not as effective in controlling experimental aspergillosis (Moonis
et al., 1992) as seen in the present study with phosphatidic acid liposomes.
In the present work the in-vivo antifungal activity of liposomal hamycin was not
enhanced by the addition of cholesterol; an observation in contrast to that observed for
liposomal amphotericin B (Ahmad et al., 1990). These observations seem to be
validated by physicochemical studies on aromatic polyenes which reveal that in
contrast with amphotericin B, aromatic polyenes bind both cholesterol and ergosterol
with equal affinity (Witzke & Bittman, 1984). At an equivalent dose (01 mg/kg) of
hamycin in phosphatidic acid liposomes with and without cholesterol we observed 60%
and 90% survival of animals respectively after seven days of therapy. In a recent report
Mehta et al. (1991) achieved in-vivo therapeutic efficacy of liposomal hamycin in the
presence of cholesterol. However, they did not analyse the comparative in-vivo
antifungal activity of hamycin in the presence and absence of cholesterol.
The data in the present study indicates that the most effective therapeutic formula-
tion of hamycin for the control of experimental aspergillosis is SPC/cholesterol/PA
liposomes (molar ratio; 4 :5:1) as it significantly reduces the toxicity of the drug,
allowing higher doses to be administered. Although the SPC/PA liposomal preparation
(9 :1 ; molar ratio) was also effective at a lower dose but due to its high toxicity could
not be used at higher doses.
Our results clearly demonstrate the potential usefulness of liposomes as a carrier in
improving the therapeutic index of hamycin in the treatment of fungal infections by
reducing its toxicity. This is particularly significant as the latter has previously severely
restricted the use of hamycin.
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